CHANGE - ANNOUNCEMENT OF CESSATION::RESIGNATION OF CHIEF SCIENTIFIC OFFICER

Issuer & Securities

Issuer/Manager

BIOLIDICS LIMITED

Securities

BIOLIDICS LIMITED - SGXE89830751 - 8YY

Stapled Security

No

Announcement Details

Announcement Title

Change - Announcement of Cessation

Date & Time of Broadcast

17-Jun-2022 18:06:03

Status

New

Announcement Sub Title

Resignation of Chief Scientific Officer

Announcement Reference

SG220617OTHR4SME

Submitted By (Co./Ind. Name)

Song Tang Yih

Designation

Executive Director and Chief Executive Officer

Description (Please provide a detailed description of the event in the box below)

Resignation of Mr. Leong Man Chun as the Chief Scientific Officer of Biolidics Limited (the "Company")

This announcement has been prepared by the Company and has been reviewed by the Company's sponsor, United Overseas Bank Limited (the "Sponsor"), for compliance with Rules 226(2)(b) and 753(2) of the Singapore Exchange Securities Trading Limited ("SGX-ST") Listing Manual Section B: Rules of Catalist.

This announcement has not been examined or approved by the SGX-ST. The SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Mr. Lim Hoon Khiat, Director, Equity Capital Markets, who can be contacted at 80 Raffles Place, #03-03 UOB Plaza 1, Singapore 048624, telephone: +65 6533 9898.

Additional Details

Leong Man Chun Age 38 Is effective date of cessation known? Yes If yes, please provide the date 01/07/2022 Detailed Reason (s) for cessation Mr. Leong Man Chun has decided to resign as the Chief Scientific Officer of the Company on his own accord to pursue other career opportunities. To provide continuity to the Group's business and operations, Mr. Leong Man Chun will continue to provide scientific advice to the Group in the capacity as an external consultant for an initial period of 24 months from 1 July 2022, which may be extended subject to mutual agreement between the Company and Mr. Leong Man Chun. Based on its enquiries, the Sponsor is satisfied that, save as disclosed in this announcement, there is no other material reason for the cessation of Mr. Leong Man Chun as the Chief Scientific Officer of the Company. Are there any unresolved differences in opinion on material matters between the person and the board of directors, including matters which would have a material impact on the group or its financial reporting? No Is there any matter in relation to the cessation that needs to be brought to the attention of the shareholders of the listed issuer? Νo Any other relevant information to be provided to shareholders of the listed issuer? No Date of Appointment to current position 01/09/2021 Does the AC have a minimum of 3 members (taking into account this cessation)? Yes

Number of Independent Directors currently resident in Singapore (taking into account this cessation)

3

Number of cessations of appointments specified in Listing Rule 704 (7) or Catalist Rule 704 (6) over the past 12 months 5

Job Title (e.g. Lead ID, AC Chairman, AC Member etc.)

Chief Scientific Officer

Role and responsibilities

Executive officer of the Company. Mr. Leong Man Chun is responsible for managing the scientific, technological, and research operations of the Group.

Familial relationship with any director and/or substantial shareholder of the listed issuer or of any of its principal subsidiaries

Nil	

Shareholding interest in the listed issuer and its subsidiaries?

Yes

Shareholding Details

792,000 ordinary shares in the Company

Past (for the last 5 years)

Nil

Present

Biomedics Laboratory Pte. Ltd.

Biolidics Pty Ltd

Clearcell Pte. Ltd.